文献速递肝胆胰外科围术期管理与 ERAS

结直肠癌肝转移微创与开腹肝切除的现代趋势:ACS-NSQIP分析

Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP.
PubMed 文献 · Surg Endosc · 2022-11-07

基于ACS-NSQIP 2015-2019年7457例结直肠癌肝转移肝切除患者(微创1367例,开腹6090例)的回顾性分析。两组临床病理特征相似,但微创组较少接受新辅助治疗(51.1% vs 64.0%,p<0.001)或同期术中消融(15.0% vs 21.3%,p<0.001),更多为肿瘤<2 cm(34.9% vs 26.8%,p<0.001)或仅1-2个肿瘤(82.8% vs 65.0%,p<0.001)。研究期间开腹和微创部分肝切除均显著增加,但开腹部分肝切除增速更快(p<0.001);解剖性切除比例不变,开腹比例更高(34.9% vs 16.4%,p<0.001)。结论:微创入路在增加,但选择性用于技术难度较低的病例。

要点

  • 微创肝切除更多用于肿瘤<2 cm或1-2个肿瘤的CRLM患者。
  • 研究期间开腹部分肝切除增速快于微创部分肝切除。
  • 解剖性切除仍以开腹为主,微创比例较低。

核心结论

  • CRLM肝切除增加源于部分肝切除增多,可能反映保留肝实质手术的应用增加。
  • 微创入路在增加,但选择性用于技术难度较低的病例。
  • 应加强微创保留肝实质技术用于更复杂切除的教育推广。

研究设计与样本

  • 回顾性队列研究,使用ACS-NSQIP数据库2015-2019年数据。
  • 共纳入7457例因CRLM行肝切除的患者,其中微创1367例,开腹6090例。

主要发现

  • 微创组新辅助治疗比例低于开腹组(51.1% vs 64.0%,p<0.001)。
  • 微创组同期术中消融比例低于开腹组(15.0% vs 21.3%,p<0.001)。
  • 微创组肿瘤<2 cm比例更高(34.9% vs 26.8%,p<0.001)。
  • 微创组仅1-2个肿瘤比例更高(82.8% vs 65.0%,p<0.001)。
  • 研究期间开腹和微创部分肝切除均显著增加,但开腹增速更快(p<0.001)。

临床怎么用

  • 微创肝切除应审慎选择病例,目前多用于肿瘤较小、数目较少的CRLM。
  • 需关注微创入路在新辅助治疗和同期消融使用上的差异。
  • 推广微创保留肝实质技术可能扩大微创在复杂切除中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical resection of colorectal liver metastasis (CRLM) provides the best opportunity for prolonged survival. Eligibility for metastasectomy has expanded with technical advancements including parenchymal-sparing hepatectomy (PSH). Meanwhile, enthusiasm for minimally invasive surgery (MIS) has increased, though this approach may be preferentially utilized for technically straightforward cases. The purpose of this study is to characterize modern trends in open versus MIS approaches to partial hepatectomy and anatomic hepatectomy for CRLM within a nationwide cohort. METHODS: The American College of Surgeons' National Surgical Quality Improvement Program (ACS-NSQIP) was used to investigate trends in MIS versus open hepatectomy for CRLM from 2015 to 2019. We examined baseline clinicopathologic and disease-related characteristics and compared trends in treatments over the study period. RESULTS: A total of 7457 patients undergoing hepatectomy for CRLM were identified (1367 MIS, 6090 open). Patients had similar clinicopathologic features between the two groups. Patients undergoing MIS resection less frequently received neoadjuvant therapy (51.1% vs 64.0%, p < 0.001) or concurrent intraoperative ablation (15.0% vs 21.3%, p < 0.001). Patients with tumors < 2 cm (34.9% vs 26.8%, p < 0.001) or only one to two tumors (82.8% vs 65.0%, p < 0.001) more commonly underwent MIS. MIS and open partial hepatectomies both significantly increased over the study period, but open partial hepatectomy increased at a greater rate than MIS (p < 0.001). Rates of anatomic resections have remained the same, with a greater proportion performed using an open approach (34.9% vs 16.4%, p < 0.001). Rates of operations consisting of > 1 concurrent partial hepatectomy are stable, but significantly more likely to be performed open (p < 0.001). CONCLUSIONS: Hepatectomy for CRLM has increased from a rise in partial hepatectomy, potentially translating to increased use of PSH. Current trends suggest MIS approaches appear to be increasing, but selectively implemented for patients with less technically demanding disease characteristics. Educational efforts should be directed towards increased dissemination of parenchymal-sparing MIS techniques for more complex resections.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Carpenter EL, Thomas KK, Adams AM, et al. Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP. Surg Endosc. 2022. PMID: 36344895. doi:10.1007/s00464-022-09749-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。